Ernexa Therapeutics (ERNAW) Long-Term Debt Issuances (2013 - 2025)

Ernexa Therapeutics has reported Long-Term Debt Issuances for 8 years, with the latest figure at $2.2 million in Q1 2025.

• For the quarter ending Q1 2025, Long-Term Debt Issuances rose 60.14% year-over-year to $2.2 million; the trailing twelve-month figure through Dec 2025 stood at $2.2 million (up 60.14% YoY), and the FY2025 full-year result was $2.2 million, up 60.14% from the prior year.
• Long-Term Debt Issuances for Q1 2025 stood at $2.2 million, up from $1.4 million in the prior quarter.
• The five-year high for Long-Term Debt Issuances was $16.5 million in Q4 2023, with the low at $1.4 million in Q1 2024.
• Historically, Long-Term Debt Issuances has averaged $6.7 million across 3 years, with a median of $2.2 million in 2025.
• The largest YoY upside for Long-Term Debt Issuances was 60.14% in 2025 against a maximum downside of 60.14% in 2025.
• Ernexa Therapeutics' Long-Term Debt Issuances stood at $16.5 million in 2023, then sank by 91.48% to $1.4 million in 2024, then surged by 60.14% to $2.2 million in 2025.
• The last three Long-Term Debt Issuances figures came in at $2.2 million (Q1 2025), $1.4 million (Q1 2024), and $16.5 million (Q4 2023), per Business Quant data.